IsoRay Inc (NYSE: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, is featured as today’s top momentum gainer since the stock gained more than 19% during the last two consecutive trading days with significant number of shares changing hands than in a normal session. During the last trading session, ISR was the star performer in the U.S. healthcare space after gaining 18.6% and closed at $3.12 while recording significant volumes of 25.9 million shares. During the past 5 trading sessions, ISR surged 34.5% with daily average traded volumes of 12.9 million shares. A strong momentum has been witnessed in the stock during the past one month after rising over 287% with daily average volumes of 13.2 million shares. The stock jumped after ISR announced to present five papers on Cesium-131 at the annual meeting of the American Brachytherapy Society (ABS) on April 03 to April 05, 2014 in San Diego, California at the Manchester Grand Hyatt. The company believes that all studies will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used.
Company Description:
With a market cap of $147.2 million, IsoRay Inc (NYSE: ISR), through its subsidiary, produces a brachytherapy seed, used to treat prostate and other cancers. The company’s seed delivers more than 90 percent to its total radiation dose in less the 33 days, reducing the incidence of common brachytherapy side effects.
1-Year Stock Chart:
Source: Bloomberg
